- Home
- HEPS vs STOK Comparison
HEPS vs STOK Comparison
Compare HEPS & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- STOK
- Stock Information
- Founded
- HEPS 2000
- STOK 2014
- Country
- HEPS Turkey
- STOK United States
- Employees
- HEPS N/A
- STOK N/A
- Industry
- HEPS Catalog/Specialty Distribution
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- STOK Health Care
- Exchange
- HEPS Nasdaq
- STOK Nasdaq
- Market Cap
- HEPS 909.5M
- STOK 740.9M
- IPO Year
- HEPS 2021
- STOK 2019
- Fundamental
- Price
- HEPS $2.96
- STOK $18.21
- Analyst Decision
- HEPS
- STOK Strong Buy
- Analyst Count
- HEPS 0
- STOK 6
- Target Price
- HEPS N/A
- STOK $26.60
- AVG Volume (30 Days)
- HEPS 617.2K
- STOK 933.9K
- Earning Date
- HEPS 07-30-2025
- STOK 08-12-2025
- Dividend Yield
- HEPS N/A
- STOK N/A
- EPS Growth
- HEPS N/A
- STOK N/A
- EPS
- HEPS N/A
- STOK 0.91
- Revenue
- HEPS $1,477,672,859.00
- STOK $199,893,000.00
- Revenue This Year
- HEPS $33.20
- STOK $409.12
- Revenue Next Year
- HEPS $25.66
- STOK N/A
- P/E Ratio
- HEPS N/A
- STOK $20.01
- Revenue Growth
- HEPS 49.45
- STOK 1218.82
- 52 Week Low
- HEPS $2.11
- STOK $5.35
- 52 Week High
- HEPS $4.05
- STOK $18.45
- Technical
- Relative Strength Index (RSI)
- HEPS 62.94
- STOK 83.33
- Support Level
- HEPS $2.61
- STOK $12.86
- Resistance Level
- HEPS $3.09
- STOK $17.61
- Average True Range (ATR)
- HEPS 0.14
- STOK 0.99
- MACD
- HEPS 0.04
- STOK 0.48
- Stochastic Oscillator
- HEPS 80.60
- STOK 96.13
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.